 Connection
Elizabeth Kessler to Anilides
This is a "connection" page, showing publications Elizabeth Kessler has written about Anilides.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.464 |
|
|
|
-
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju?rez VM, Hsieh JJ, Basso U, Shah AY, Su?rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 03 04; 384(9):829-841.
Score: 0.181
-
Neuwelt AJ, Mathur S, Johnson AT, Kessler ER, Bowles DW. Cabozantinib use in renal cell carcinoma. Drugs Today (Barc). 2017 May; 53(5):299-307.
Score: 0.139
-
Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc). 2011 Nov; 47(11):857-68.
Score: 0.095
-
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Su?rez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 07; 23(7):888-898.
Score: 0.049
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|